Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes correct Timster .
They are not actually disclosing targets for Canseek at this time.
What we do know is that Avacta receive $9.5m for achieving the first target, $8.5m for each subsequent target plus royalties on future sales.
Nice little earners going forward I would say.
Onwards Avacta.
Point are not trialing CanSEEK at the moment it's not in the clinic.
The splash trial is this https://clinicaltrials.gov/ct2/show/NCT02743741
Gmcc is suggesting that if successful they would use CanSEEK to deliver it in a more targeted way (i.e FAP activated)
https://www.pointbiopharma.com/our-products/pipeline/canseek
Is that what you are saying gmcc?
gmcc, interesting find you called to attention PB to publish Abstract at ESMO Congress, Abstract is titled Efficacy & Safety of 177Lu-PNT 2002 prostate cancer (mcrpc). This drug has FDA & UK approval and is used by Novartis in their Pluvicto trials for the above cancer.
Does this mean the difference between the Novartis trial and the PB Splash trial is in the delivery process (CanSeek v Pluvicto). If so would this not be very exciting news or am I misunderstanding the technology.
In the Webinar, Understanding the PNT 2002 Splash Trial two key speakers are listed, one being Dr Oliver Sartor. He led or co-led multiple National & International Clinical studies including 3 Radio pharmaceutical phase 3 studies pivotal for FDA approval in Prostate cancer. Lu-177-PSMA -617 being one of them?
His involvement imo speaks volumes.
Looking forward PB : PSMA "obtained an exclusive license of Avacta’s patent rights to use, develop, manufacture and commercialize any FAP-activated PSMA targeted radiopharmaceutical "
CanSeek system of Point is based on Avacta's pre|CISION technology which creates FAP-activated prodrugs. In this case, an FAP-activated radiopharmaceutical. Point could take their PSMA-targeted drug PNT2002 and use pre|CISION to create a FAP-activated prodrug version. Could be first Canseek candidate choice if " SPLASH" gets approved for use . .
PNT stock price $ 8.68 ? 0.45 (5.47%) today
----------------------
"POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
The abstract is titled “Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH” (Abstract #1400P) and focuses on efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the Company’s phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC)."
Market not open yet, timster
Give hurstbot a chance
Bego currently warming up with star jumps
Don't forget all these gene therapy conferences
http://www.genetherapynet.com/conferences-2022.html
As important as ASCO? Mind blowing SP reaction after that one....
Listened to Webinar yesterday and Paris coming up!
https://www.esmo.org/
For anyone interested, but mostly for Hurst
https://hub.pointbiopharma.com/controlarm
Hi Timster Yes & No : Avacta rely on PB getting all their radiopharmaceuticals drugs approved for use , otherwise CanSEEK™ irrevalent . So down the road could be very relevant .
Forgot to add I'd expect some very large prints that day plus BEGO on or even over the bid...
Incredible stuff, so the drug that is currently in a clinical trial that has nothing to do with Avacta, that's a must watch, I can't wait....
I'm so excited I almost spilled my beer (almost)!
Super news!
FYI:
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, announced that next week, on Thursday, August 18, 2022 at 12:00 PM ET, the Company will be presenting a 45-minute educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”.